iRGD peptide 1 TFA |
| Katalog-Nr.GC60204 |
iRGD-Peptid 1 TFA ist das prototypische tumorspezifische gewebedurchdringende Peptid, das Medikamente tief in extravaskulÄres Tumorgewebe einbringt. iRGD-Peptid 1 TFA hat antimetastatische AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers drugs deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity[1].
iRGD peptide 1 (iRGD) inhibits migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. iRGD peptide 1 induces dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects are prominently displayed when the cells are seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins[1].
iRGD peptide 1 (amino acid sequence: CRGDKGPDC; 4 μmol/kg; intravenous injection; every other day; for 21 days) potently inhibits spontaneous metastasis in mice[1].
[1]. Kazuki N Sugahara, et al. Tumor-penetrating iRGD Peptide Inhibits Metastasis. Mol Cancer Ther. 2015 Jan;14(1):120-8.
| Cas No. | SDF | ||
| Formula | C37H60F3N13O16S2 | M.Wt | 1064.08 |
| Löslichkeit | Storage | ||
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9398 mL | 4.6989 mL | 9.3978 mL |
| 5 mM | 0.188 mL | 0.9398 mL | 1.8796 mL |
| 10 mM | 0.094 mL | 0.4699 mL | 0.9398 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *